Vassella, Erik

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer

Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 55

Somatic RIT1 delins in arteriovenous malformations hyperactivate RAS-MAPK signaling amenable to MEK inhibition

Kapp, F. G., Bazgir, F., Mahammadzade, N., Mehrabipour, M., Vassella, E., Bernhard, S. M., Döring, Y., Holm, A., Karow, A., Seebauer, C., et al. (2024) · Angiogenesis

Vascular Malformations and HemangiomasVascular Malformations Diagnosis and Treatment

Cited by 20